The headline pairs an extension of Regeneron Pharmaceuticals’ BARDA deal with long-term Libtayo data described as holding up. But it gives no contract terms or clinical results, so it’s unclear what changed or how the findings were measured.
Investor takeaway: The headline reports a BARDA deal extension and a Libtayo data update, but the supplied information doesn’t quantify either one.
REGN.US closed at US$912.76
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$93.55B
P/E
20.0x
Div. yield
0.41%
Div. / share
$3.70
52W high
$991.73
52W low
$590.83
1W change
-4.30%
Beta
0.10
Analyst Price Targets
Based on 28 analysts covering REGN · as of Nov 9, 2026
Wall Street analysts forecast REGN stock price to rise 6.3% over the next 12 months.
Consensus
Buy4.21 / 5.00
Avg. Target
C$977.93
+6.3% Upside
Current Price
C$919.96
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
46.4%
Annualized
90-Day Vol
36.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$1099.82
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$976.38 | C$831.98 – C$1145.85 |
| 60 trading days | C$1036.26 | C$826.36 – C$1299.48 |
| 90 trading days | C$1099.82 | C$833.55 – C$1451.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
The supplied quote shows a 1.73% one-day gain. Trading volume was 73,895 shares, compared with a 20-day average of 935,617.
Bull case
The headline points to two developments investors may want to follow: an extended BARDA deal and long-term Libtayo data described as holding up.
Bear case
The supplied information includes no contract terms, study results, patient numbers or other supporting details. That limits what investors can conclude from the headline.
What the BARDA and Libtayo headline says
The November 8 headline says Regeneron extended a BARDA deal and that long-term Libtayo data “holds up.” It doesn’t give the agreement’s value, duration, scope or specific BARDA program. Nor does it describe the Libtayo study, its participants, endpoints, results or follow-up period. The headline reports the developments, but doesn’t show their financial scale or clinical significance. You can find the company’s listing on the Regeneron stock page, but the supplied information includes no further terms or data.
The supplied trading figures
Regeneron’s last close was US$912.76. The stock gained 1.73% over one day, fell 4.30% over one week and rose 23.23% over one month. Its year-to-date change was +18.96%. Latest volume was 73,895 shares, or 0.91 times the 20-day average of 935,617 shares. These figures describe the supplied quote and trading periods. They don’t show that the BARDA or Libtayo news caused the share-price movement. Quote and listing details are also available on the REGN stock page.
What to watch for in further details
The headline leaves two key questions unanswered. For the BARDA extension, it doesn’t say what work the agreement covers or how long it runs. For Libtayo, it provides no long-term results or explanation of what “holds up” means. Assessing either development depends on those details, which aren’t included here.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
